NXSTAGE MEDICAL acquired by FRESENIUS

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally. The strategic rationale includes leveraging EUROIMMUN’s high-growth profile (averaging 19% revenue growth over five years) to accelerate PerkinElmer’s overall earnings. Additionally, the acquisition allows PerkinElmer to drive EUROIMMUN’s specialized solutions through its well-established U.S. commercial channels.

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership. The primary strategic rationale underpinning the deal is to massively accelerate SERB's developmental roadmap. The freshly injected capital and strategic guidance will be explicitly deployed to fuel ongoing geographic expansion and aggressively pursue the continuous acquisition of complementary specialty pharmaceutical products and synergistic businesses.

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology.

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting.

The acquisition of Vention Advanced Technologies by Nordson Corporation signifies a major step in the group’s expansion into the high-growth medtech sector. The strategic logic of this transaction hinges on a "market-balancing" maneuver, merging the target’s industry-leading technical operational depth in interventional delivery systems with the buyer’s established scale in precision fluid management. This alignment equips the combined organization with the scientific talent and manufacturing hardware necessary to address the increasing demand for minimally invasive medical solutions across North America, Europe, and Asia. This maneuver allows the organization to execute a definitive structural expansion of its technical suite, particularly in the single-use fluid management and biomaterial delivery segments.

Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.

Ecolab has completed the acquisition of 100% of Laboratoires Anios from Ardian and the Letartre family. This transaction represents a definitive exit for the private equity firm Ardian, which had supported the founding family in a 2013 LBO following a previous ownership cycle by Air Liquide. The strategic rationale for Ecolab is to establish a dominant foothold in the European hospital disinfection market, a segment where it was previously underrepresented. For Anios, the merger provides a global springboard, particularly to accelerate its expansion into the Chinese market. Over the three years of Ardian’s ownership, Anios achieved a 25% increase in revenue and a 55% jump in EBITDA, driven by a series of five strategic "bolt-on" acquisitions.

On September 19, 2016, ArchiMed completed the acquisition of a majority stake in Polyplus Transfection, a prominent player in the biologics delivery space. The transaction was executed as a proprietary deal, seamlessly completed outside of any formal auction process, and was heavily supported by the existing management team. This strategic move represents a textbook platform investment for the private equity firm, executed through its Med 1 fund, capitalizing on their deep sector expertise. The strategic rationale behind this transaction is deeply rooted in the strong secular growth currently observed across biologics-based therapeutics and cell therapies. By acquiring this niche champion, the firm aims to leverage its extensive global healthcare network to accelerate international expansion and push proprietary product development into a higher gear. The deal is expected to be highly value-accretive, combining vast financial resources and operational capabilities with specialized proprietary transfection technology. Market implications are substantial, signaling increased sector consolidation within the highly fragmented life sciences supply chain and highlighting the premium placed on specialized reagent manufacturers.

Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited. This deal marked the transition from a regional SME to a national leader with international ambitions. The roadmap focused on external growth and digital transformation.